Core Viewpoint - China National Pharmaceutical Group (China Biologic) has entered into an exclusive licensing agreement with Sanofi for the global development, production, and commercialization of the JAK/ROCK inhibitor, Ruxolitinib, which is expected to generate significant upfront and milestone payments for the company [1][2]. Group 1: Licensing Agreement Details - The agreement grants Sanofi exclusive rights to develop, produce, and commercialize Ruxolitinib globally [1]. - China Biologic will receive an upfront payment of $135 million and potential milestone payments up to $1.395 billion based on development, regulatory, and sales achievements [1]. - The agreement includes tiered royalties based on annual net sales of Ruxolitinib, with the royalties being in the double digits [1]. Group 2: Product Information - Ruxolitinib is a first-in-class oral small molecule JAK/ROCK inhibitor that targets both the JAK/STAT pathway and the ROCK pathway to reduce inflammation and fibrosis [1]. - The drug has been approved by the National Medical Products Administration (NMPA) in China for first-line treatment of intermediate-2 or high-risk primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), and post-essential thrombocythemia myelofibrosis (PET-MF) in adult patients [2]. - Ruxolitinib is also showing potential in treating chronic graft-versus-host disease (cGVHD), having entered Phase III clinical trials in China and being included in the breakthrough therapy program by the CDE [2]. - Clinical data published in the journal "Blood" indicates that Ruxolitinib has superior 12-month failure-free survival rates compared to other approved therapies and shows strong treatment responses in fibrotic-dominant organs, with potential to overcome resistance to other treatments [2].